A comprehensive lung cancer screening program that uses CT scan technology developed at Intermountain Medical Center in Salt Lake City may provide smokers with a more precise way of determining if they have lung cancer. The screening program drew on the results of the National Lung Screening Trial, a comprehensive trial in which CT scans were compared…
iCAD Inc., a company that delivers innovative cancer detection and radiation therapy solutions, recently presented updated clinical data on the use of intraoperative radiation therapy (IORT) with the Company’s Xoft Axxent Electronic Brachytherapy System to treat patients with early-stage breast cancer at the San Antonio Breast Cancer Symposium held in December in San Antonio, Texas. Management of Nashua, New…
The U.S. Food and Drug Administration (FDA) has approved Immunomedics’ antibody-drug conjugate Trodelvy (sacituzumab govitecan) to treat triple-negative breast cancer (TNBC) patients who already tried at least two previous therapies for metastatic disease. The approval, given under FDA’s Accelerated Approval Program and about five weeks ahead of an expected decision, makes Trodelvy the first antibody-drug conjugate available for hard-to-treat…
Researchers in the U.K. and Germany report that lycopene, a carotenoid pigment present in tomatoes, can protect human lymphoid cells against the harmful effects of gamma radiation during radiation therapy, a common treatment for cancer, and could be used as a dietary intervention. The study, “A dramatic effect of oxygen on protection of human cells against…
iCAD Inc. recently announced its latest innovative imaging tool for early detection of breast cancer based on tomosynthesis computer-aided detection (CAD). The technology is on display at the European Congress of Radiology (ECR) in Vienna, Austria, through March 6. According to a study published in the journal Cancers, breast cancer is the most common invasive type of cancer in women,…
A Phase 1b/2 trial investigating Vigeo Therapeutics‘ VT1021 as a stand-alone treatment for advanced ovarian cancer and other tumor types has dosed the first patients in its dose expansion stage. Early results are expected later this year. Roughly 75 adults will be enrolled in this stage of the trial (NCT03364400). Besides ovarian cancer, the other groups…
Madrid-based PharmaMar has submitted the protocol for a Phase 2 trial to the Spanish Medicines and Healthcare Products Agency (AEMPS) to test its multiple myeloma therapy Aplidin (plitidepsin) in people with COVID-19 pneumonia. The trial, named APLICOV, aims to recruit 160 patients across multiple sites in Spain and assess if Aplidin reduces the proportion of…
A Phase 3 trial of Bavencio (avelumab) in people with squamous cell carcinoma of the head and neck (SCCHN) was ended early due to a lack of effectiveness seen in an interim analysis, the companies that developed and are marketing the treatment announced. Data from the study, named JAVELIN Head and Neck 1oo (NCT02952586), showed that…
The first patient has been dosed in Antengene‘s Phase 1 clinical trial investigating the dual inhibitor ATG-019, alone or in combination with niacin extended release, for people with non-Hodgkin’s lymphoma or advanced solid tumors. ATG-019 is being developed as KPT-9274 by Karyopharm Therapeutics, but Antengene acquired its development and commercialization rights in several Asian countries and…
A combination of Vaccitech’s experimental vaccine VTP-800 and Opdivo (nivolumab) appears to be a safe and potentially effective treatment for men with metastatic castration resistant prostate cancer (mCRPC), according to early data from a Phase 2a part of clinical trial. The open-label study (NCT03815942), called ADVANCE, may still be recruiting up to 36 patients in the U.K. It is sponsored…
